#GenomicMedicine | Explore Tumblr Posts and Blogs

dpathucgconforences · 7 months

Text

Call for Abstract!!! The abstract Submission deadline is Today. Submit an abstract for the CME/CPD-accredited 11th World Digital Pathology & AI UCGCongress from December 15-17, 2023, in Holiday Inn Dubai, Al Barsha, UAE & Virtual

.WhatsApp us: https://wa.me/442033222718?text=

Submit your abstract here: https://digitalpathology.ucgconferences.com/submit-abstract/

#LabToPatient #ScienceAndMedicine #ResearchImpact #PrecisionMedicine #PersonalizedMedicine #Genomics #TargetedTherapy #HealthcareInnovation #GenomicMedicine #PatientCare #MedicalResearch #CustomizedTreatment

0 notes

healthcaretechnologynews · 10 months

Text

Navigating CYP2C19 Testing: A Deep Dive into Its Application and Utilization in the US Market

Precision medicine is steering the way forward in the healthcare landscape, and CYP2C19 testing stands as a shining example. This blog discusses the intricate realm of CYP2C19 testing, exploring its applications and utilization within the US market and shedding light on how this genetic testing is shaping patient care and treatment strategies.

Read Full Blog Here: https://www.grgonline.com/post/navigating-cyp2c19-testing-a-deep-dive-into-its-application-and-utilization-in-the-us-market

1. Genetic Key to Personalized Care:

Imagine CYP2C19 testing as a genetic key that unlocks personalized care. This testing focuses on a specific gene variant crucial in metabolizing various medications. Understanding an individual’s genetic makeup empowers healthcare providers to tailor treatment plans accordingly.

2. Pharmacogenomics at Play:

CYP2C19 is a prime example of pharmacogenomics in action. This field studies how genetic variations influence a person’s response to medications. CYP2C19 testing identifies specific variants that can impact how certain drugs are metabolized, leading to variations in efficacy and potential side effects.

3. Application in Cardiovascular Care:

In the US market, CYP2C19 testing has found significant applications in cardiovascular care. Certain antiplatelet medications, such as clopidogrel, are metabolized through the CYP2C19 pathway. Testing helps determine if a patient’s genetic makeup affects their response to such drugs, enabling personalized dosage adjustments.

4. Informing Treatment Decisions:

CYP2C19 testing guides treatment decisions in cases of stent placement or acute coronary syndromes. Patients with reduced enzyme activity due to genetic variants may not effectively metabolize clopidogrel. This insight prompts healthcare providers to consider alternative medications or adjust dosages for optimal outcomes.

5. Psychiatric Medication Management:

Beyond cardiovascular care, CYP2C19 testing finds application in psychiatry. Certain antidepressants and antipsychotics are also metabolized through this pathway. Testing helps determine the right medication and dosage for individuals, minimizing adverse effects and improving therapeutic outcomes.

6. Considerations for Surgical Procedures:

CYP2C19 testing extends its influence on surgical scenarios. Patients undergoing surgery may require pain management with medications like codeine. Genetic variations can impact codeine’s conversion into active form, potentially affecting pain relief. CYP2C19 testing assists healthcare providers in selecting appropriate pain management strategies.

7. Drug-Drug Interactions:

In the US market, CYP2C19 testing plays a crucial role in preventing drug interactions. Some drugs can inhibit or induce the CYP2C19 enzyme, affecting the metabolism of other medications. Testing helps healthcare providers anticipate potential interactions and adjust treatment plans accordingly.

8. Implementing Precision Medicine:

CYP2C19 testing exemplifies the integration of precision medicine into clinical practice. Healthcare providers can customize treatments to optimize efficacy and safety by understanding a patient's genetic profile. This approach marks a significant shift from the one-size-fits-all paradigm.

In Conclusion:

CYP2C19 testing is a cornerstone in the journey toward personalized medicine within the US market. With applications spanning cardiovascular care, psychiatric treatment, surgical considerations, and drug interactions, this genetic testing offers a deeper understanding of how individuals metabolize medications. As healthcare evolves, CYP2C19 testing exemplifies the power of genetics in guiding treatment decisions and revolutionizing patient care.

Visit our website now: https://www.grgonline.com/

#genetic testing #healthcare #precision medicine #genomicmedicine #genetics #Clinical Testing #personalized medicine #us healthcare #CYP2C19 Testing #Navigating CYP2C19 #Precision Healthcare

0 notes

usnewsper-business · 10 months

Text

Can't we all just get along? Making precision medicine available for all #genomicmedicine #individualizedmedicine #personalizedmedicine #precisionmedicine #targetedtherapy

#Health #genomicmedicine #individualizedmedicine #personalizedmedicine #precisionmedicine #targetedtherapy

0 notes

everythingwaschocolateandsugar · 1 year

Text

Challenges and Opportunities in In Vitro Diagnostics (IVD) Market: An Overview

In Vitro Diagnostics (IVD) is a rapidly growing market that involves the use of medical diagnostic tests and equipment to diagnose diseases and conditions in a laboratory setting. The IVD market is expected to continue to grow in the coming years, driven by increasing demand for personalized medicine and point-of-care testing. However, the market also faces a number of challenges and opportunities that need to be considered.

Request for free Sample PDF: https://www.nextmsc.com/in-vitro-diagnostics-ivd-market/request-sample

Challenges

Regulatory challenges: The IVD market is highly regulated, with strict standards and guidelines that must be followed. Compliance with these regulations can be complex and time-consuming, which can make it difficult for smaller companies to enter the market.

Reimbursement issues: Reimbursement for diagnostic tests can be a challenge, with varying reimbursement policies across different regions and countries. This can impact the adoption of new tests and technologies, as healthcare providers may be hesitant to invest in tests that are not fully reimbursed.

Data management: The large amount of data generated by IVD tests can be a challenge to manage and analyse, particularly as more tests move towards digital and AI-based technologies.

Economic and political uncertainty: Economic and political uncertainty can impact the IVD market, particularly in emerging markets where funding and resources may be limited.

Opportunities

Personalized medicine: The growing focus on personalized medicine is driving growth in the IVD market, as healthcare providers seek to tailor treatments to individual patients. Advances in genomic testing and liquid biopsy technologies are helping to make personalized medicine a reality.

Point-of-care testing: Point-of-care testing is a rapidly growing segment of the IVD market, driven by demand for faster and more efficient diagnostic tests. The development of portable and easy-to-use diagnostic tests is opening up new opportunities in this area.

Digital and AI-based technologies: Digital and AI-based technologies are transforming the IVD market, with advances in data management, analysis, and interpretation. These technologies have the potential to improve the accuracy and efficiency of diagnostic tests, leading to better patient outcomes.

Emerging markets: The IVD market is expanding rapidly in emerging markets, driven by increasing demand for healthcare services and rising prevalence of chronic diseases. This presents new opportunities for companies to expand their reach and tap into new markets.

Conclusion

The IVD market faces a number of challenges, but also presents significant opportunities for growth and innovation. As healthcare providers seek to deliver more personalized and efficient care, the demand for IVD tests and equipment is likely to continue to grow. Companies that are able to navigate the regulatory landscape and develop innovative new products that meet the needs of patients and healthcare providers will be well positioned to succeed in this dynamic and rapidly evolving market.

0 notes

aserougi · 1 year

Text

This biotech says mice live longer after genetic reprogramming

t.ly/m_Jb http://dlvr.it/Sgcfn4 t.ly/9DBh

#Biotechnology #Genomicmedicine

0 notes

globalinsightblog · 3 months

Text

AI-Powered Genomics: Transforming Healthcare 2024-2033

The Artificial Intelligence in Genomics Market is experiencing unprecedented growth and innovation from 2024 to 2033, revolutionizing how we understand, diagnose, and treat genetic diseases.

With the exponential increase in genomic data generated from various sources such as sequencing platforms and electronic health records, AI technologies are indispensable for extracting meaningful insights efficiently. AI algorithms are adept at identifying patterns, predicting disease risks, and guiding personalized treatment strategies based on an individual's genetic makeup. Moreover, the integration of AI with other emerging technologies like blockchain ensures the security, integrity, and interoperability of genomic data, fostering collaboration and accelerating research breakthroughs.

#AIinGenomics #GenomicMedicine #PrecisionHealth #PersonalizedMedicine #GeneticDiagnostics #MachineLearning #HealthcareInnovation #DataAnalytics #BlockchainTechnology #HealthTech #Bioinformatics #PredictiveAnalytics #GenomicData #TherapeuticInnovation #FutureofHealthcare

0 notes

yedita83 · 6 years

Photo

Hoy los seminarios bibliográficos estuvieron aún más interesantes~☆ Artículos de casos clinicos e investigación en laboratorios de Países Asiáticos, en estos dos casos fueron en Japón (Osaka y Tokio) y China (Hong Kong)~♡ lalala~ #geneticdepartment #molecularbiology #dna #cytogenetics #cytogenomic #genomicmedicine #chromosomesrules #qcb #uanl #proudchemist (en Facultad de Medicina. UANL)

#geneticdepartment #cytogenomic #chromosomesrules #genomicmedicine #proudchemist #cytogenetics #qcb #dna #molecularbiology #uanl

0 notes

sciencespies · 5 years

Text

Analysis of global cancer data shines light on alternative gen 'switches' in tumors

https://sciencespies.com/biology/analysis-of-global-cancer-data-shines-light-on-alternative-gen-switches-in-tumors/

Analysis of global cancer data shines light on alternative gen 'switches' in tumors

The image illustrates the human genome (blue), and 3 alternative promoters (indicated by arrows) that activate and transcribe 3 different RNAs from the same gene. Credit: Radhika Patnala, Cell, DOI: 10.1016/j.cell.2019.08.018

More

Scientists from the Agency for Science, Technology and Research (A*STAR)’s Genome Institute of Singapore (GIS) have discovered that many human cancers exhibit widespread alterations in gene activation, where the same gene uses different start positions to generate alternate gene products. These alterations, previously undetected by earlier methods of analysis, may identify novel biomarkers for predicting cancer patient survival and new targets for therapies. The study was published in Cell on 5 September 2019 and featured on the journal’s cover.

The human genome contains all our genes. The region which controls where a gene starts is called the promoter, or a “switch” that turn on genes in the genome. Many genes have multiple promoters, and this can lead to different functions even from the same gene.

Prior to this study, cancer researchers lacked a comprehensive survey of alternative promoters in cancer genes, and whether different promoters leads to differences in clinical behavior of cancer patients.

To fill the gap, the team designed a specialized software called proActiv to detect activated promoters on a genome-wide scale. The underlying algorithm in proActiv is applicable to RNA1-profiling data, which is routinely produced by hundreds of laboratories worldwide to study cancer. The team applied proActiv to a large collection of publicly-available data from over 18,000 cancer samples, and discovered that promoters in cancer genes are frequently different from their cancer-free counterparts. They also uncovered specific activated promoters that are linked to the survival rate of cancer patients, representing a new class of biomarkers.

Dr. Jonathan Göke, Computational Biologist at the GIS and co-senior author of the study, explained, “We designed proActiv to work on RNA-profiling and it enables us to use the largest collection of data possible. At first that was very challenging. It was akin to solving a puzzle with thousands of pieces, where many of the pieces are almost identical. However, proActiv zooms in specifically on the unique puzzle pieces for each promoter, allowing detection of different promoters with high accuracy. The amazing part is that through this simple idea, we suddenly could analyze terabytes of data that was available to the public. The data was out there, but the information about promoters was hidden. With the new method, we managed to uncover this hidden information.”

Commenting on the study, Dr. Andrew Futreal, Department Chair of GenomicMedicine at MD Anderson Cancer Center said, “The scale of this global study is impressive. It reveals that the usage of alternate promoters is a common feature of many cancer types. These findings will inspire more research into what controls this switching, and how we can use this information to improve outcomes for cancer patients.”

Prof Patrick Tan, co-senior author, Executive Director of the GIS, and a faculty member of Duke-NUS and Cancer Science Institute Singapore (CSI),said, “RNA-profiling is very frequently used in medical research. By using proActiv, scientists will be able to identify promoters without any additional experimental cost, which makes this very interesting to many research groups worldwide and opens the possibilities to explore alternative promoters in other diseases.” With the aim of advancing research in the wider scientific community, the team has deposited proActiv into the public domain, where it is free to use for other academic researchers.

The findings highlight that a promoter is a biomarker for cancer, but this does not imply that promoters cause a more severe form of cancer. “We have yet to determine if these promoters act like an emergency sign that is turned on because of a fire, or if these promoters are the fire itself,” added Dr. Göke. For the GIS team in Singapore, the study is the first step towards many new possibilities to explore these questions, and to better understand the role of our genes in cancer.

Join us on Facebook or Twitter for a regular update.

Explore further

Scientists uncover the intricacies of the ‘on/off switch’ that creates cell differentiation

More information: Deniz Demircioğlu et al. A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters, Cell (2019). DOI: 10.1016/j.cell.2019.08.018

Journal information: Cell

Provided by Agency for Science, Technology and Research (A*STAR), Singapore

Citation: Analysis of global cancer data shines light on alternative gen ‘switches’ in tumors (2019, September 6) retrieved 6 September 2019 from https://phys.org/news/2019-09-analysis-global-cancer-alternative-gen.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

#Biology

0 notes

justin-aptaker · 6 years

Link

via Twitter https://twitter.com/justin_aptaker

#IFTTT #Twitter

0 notes